Individual or combination treatments with lapatinib and paclitaxel cause potential bone loss and bone marrow adiposity in rats. Issue 3 (27th September 2018)

• Record Type: Journal Article
• Authors: Lee, Alice M. C.; Bowen, Joanne M.; Su, Yu‐Wen; Plews, Erin; Chung, Rosa; Keefe, Dorothy M. K.; Xian, Cory J.
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 3(2019)
• Page Start: 4180
• Page End: 4191
• Publication Date: 2018-09-27
• Subjects: bone and bone marrow damage -- breast cancer chemotherapy -- ErbB1 and ErbB2 dual inhibitor; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.27705
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Cancer treatments with cytotoxic drugs have been shown to cause bone loss. However, effects on bone are less clear for ErbB‐targeting tyrosine kinase inhibitors or their combination use with cytotoxic drugs. This study examined the effects of individual or combination treatments with breast cancer drugs lapatinib (a dual ErbB1/ErbB2 inhibitor) and paclitaxel (a microtubule‐stabilizing cytotoxic agent) on bone and bone marrow of rats. Wistar rats received lapatinib (240 mg/kg) daily, paclitaxel (12 mg/kg) weekly, or their combination for 4 weeks, and effects on bone/bone marrow were examined at the end of week 4. Microcomputed tomographical structural analyses showed a reduction in trabecular bone volume in tibia following the lapatinib, paclitaxel or their combination treatments ( P < 0.05). Histomorphometry analyses revealed marked increases in bone marrow adipocyte contents in all treatment groups. Reverse transcription polymerase chain reaction gene expression studies with bone samples and cell culture studies with isolated bone marrow stromal cells showed that the all treatment groups displayed significantly reduced levels of osterix expression and osteogenic differentiation potential but increased expression levels of adipogenesis transcription factor peroxisome proliferator‐activated receptor γ. In addition, these treatments suppressed the expression of Wnt10b and/or increased expression of Wnt antagonists (secreted frizzled‐related protein 1, Dickkopf‐related protein 1 and/or sclerostin). Furthermore, all treatment groups showed increased numbers of bone‐resorbing osteoclasts on trabecular bone surfaces, although only the lapatinib group displayed increased levels of osteoclastogenic signal (receptor activator of nuclear factor κΒ ligand/osteoclastogenesis inhibitor osteoprotegrin expression ratio) in the bones. Thus, inhibiting ErbB1 and ErbB2 by lapatinib or blocking cell division by paclitaxel or their combination causes significant trabecular bone loss and bone marrow adiposity involving a switch in osteogenesis/adipogenesis potential, altered expression of some major molecules of the Wnt/β‐catenin signalling pathway, and increased recruitment of bone‐resorbing osteoclasts. Abstract : Cancer treatments with cytotoxic drugs have been shown to cause bone loss. However, effects on bone are less clear for ErbB‐targeting tyrosine kinase inhibitors or their combination use with cytotoxic drugs. This study shows that inhibiting ErbB1 and ErbB2 by lapatinib or blocking cell division by paclitaxel or their combination causes significant trabecular bone loss and bone marrow adiposity involving a switch in osteogenesis/adipogenesis potential, expression of some major molecules of the Wnt/b‐catenin signal pathway, and an increase in osteoclast recruitment.